No Data
European Equities Close Mostly Higher in Friday Trading; Novo Nordisk's Catalent Acquisition Faces Roadblock
Weight loss drug expansion plan faces obstacles! Consumer groups in the USA demand the FTC to block the shareholders of novo-nordisk a/s from acquiring catalent.
On Thursday, consumer groups and two large unions in the usa urged the Federal Trade Commission (FTC) to block the acquisition contract of drug manufacturer catalent by novo-nordisk a/s shareholder Novo Holdings.
Novo Nordisk-Catalent Deal Faces Opposition From Consumer Groups Over Competition Concerns
Consumer groups are requesting the FTC in the usa to block Novo Holdings' acquisition of catalent.
According to Reuters on October 18th, consumer groups and two major unions in the USA urged the Federal Trade Commission (FTC) to block the acquisition contract of drug manufacturer Catalent by Novo Nordisk A/S's shareholder Novo Holdings, stating that the deal threatens competition in the weight loss and cutting-edge genetic therapy areas. The Public Interest Research Group, Service Employees International Union (SEIU), and other organizations expressed concerns about this $16.5 billion deal in a letter to the FTC. Last week, Democratic Senator Warren also called on the FTC to closely monitor this transaction, citing similar reasons.
Consumer Groups Ask FTC to Block Novo Holdings-Catalent Deal
Catalent Stock Flat Following the Sell Agreement With Ardena